Estrella Immunopharma (ESLA) Income from Continuing Operations (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Income from Continuing Operations of 2292064.0 for Q1 2026, down 8.92% year-over-year from 2516602.94 in Q1 2025, and down 207.57% quarter-over-quarter from 2130825.0 in Q4 2025.
Estrella Immunopharma (ESLA) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Income from Continuing Operations for 6 consecutive years, with 2292064.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 8.92% year-over-year to 2292064.0; the TTM figure through Mar 2026 stood at 10507266.0 (up 43.95% YoY), while the FY2025 annual figure was 10319513.0, down 16.64% from the prior year.
- Income from Continuing Operations retreated to 2292064.0 in Q1 2026 per ESLA's latest filing, from 2130825.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 2130825.0 in Q4 2025 and bottomed at 8402355.0 in Q1 2023.
- Historically, Income from Continuing Operations has averaged 2807375.76 across 5 years, with a median of 2104311.0 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 17146.89% — and 2025, when it soared 148.13%.
- Estrella Immunopharma's Income from Continuing Operations stood at 5722432.0 in 2022, then surged by 82.16% to 1020624.0 in 2023, then sank by 333.76% to 4427027.0 in 2024, then jumped by 148.13% to 2130825.0 in 2025, then sank by 207.57% to 2292064.0 in 2026.
- Business Quant data shows ESLA's Income from Continuing Operations at 2292064.0 in Q1 2026, 2130825.0 in Q4 2025, and 4801149.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | -2.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.31 Mn |
| Mar 31, 2026 | -2.29 Mn |
| Dec 31, 2025 | 2.13 Mn |
| Sep 30, 2025 | -4.80 Mn |
| Jun 30, 2025 | -5.54 Mn |
| Mar 31, 2025 | -2.10 Mn |
| Dec 31, 2024 | -4.43 Mn |
| Sep 30, 2024 | -7.80 Mn |
| Jun 30, 2024 | -4.42 Mn |
| Mar 31, 2024 | -469,530.00 |
| Dec 31, 2023 | -1.02 Mn |
| Sep 30, 2023 | -1.87 Mn |
| Jun 30, 2023 | -139,329.00 |
| Mar 31, 2023 | -8.40 Mn |
| Dec 31, 2022 | -5.72 Mn |
| Sep 30, 2022 | -344,863.00 |
| Jun 30, 2022 | -359,586.00 |
| Mar 31, 2022 | -141,252.00 |
| Dec 31, 2021 | -135,797.00 |
| Sep 30, 2021 | -107,547.00 |